Mohd Yusmaidie Aziz1, Kurt-Jürgen Hoffmann2, Michael Ashton3. 1. Unit for Pharmacokinetics and Drug Metabolism, Dept. Pharmacology, Sahlgrenska Academy at University of Gothenburg, Sweden; Advanced Medical and Dental Institute, Universiti Sains Malaysia (USM), Malaysia. 2. Unit for Pharmacokinetics and Drug Metabolism, Dept. Pharmacology, Sahlgrenska Academy at University of Gothenburg, Sweden. 3. Unit for Pharmacokinetics and Drug Metabolism, Dept. Pharmacology, Sahlgrenska Academy at University of Gothenburg, Sweden. Electronic address: michael.ashton@gu.se.
Abstract
PURPOSE: This study aimed to develop a sensitive, quantitative assay for the antimalarial piperaquine (PQ) and its metabolites M1 and M2 in human plasma. RESULTS: Analytes were gradiently separated on a C18 column and detected with a Sciex API 4000 MS/MS with an ESI source operated in the positive ion mode with deuterated PQ as internal standard. The response was linear in the range 3.9-2508nM with a runtime of 7.0min per sample. The method was applied to clinical samples from healthy volunteers. CONCLUSION: This LC-MS/MS method for the simultaneous quantitation of PQ and two of its metabolites in plasma may prove helpful for assessment of metabolite safety issues in vivo.
PURPOSE: This study aimed to develop a sensitive, quantitative assay for the antimalarial piperaquine (PQ) and its metabolites M1 and M2 in human plasma. RESULTS: Analytes were gradiently separated on a C18 column and detected with a Sciex API 4000 MS/MS with an ESI source operated in the positive ion mode with deuterated PQ as internal standard. The response was linear in the range 3.9-2508nM with a runtime of 7.0min per sample. The method was applied to clinical samples from healthy volunteers. CONCLUSION: This LC-MS/MS method for the simultaneous quantitation of PQ and two of its metabolites in plasma may prove helpful for assessment of metabolite safety issues in vivo.